According to our (Global Info Research) latest study, the global Alfuzosin Hydrochloride Sustained Release Tablets market size was valued at US$ 383 million in 2025 and is forecast to a readjusted size of US$ 511 million by 2032 with a CAGR of 4.2% during review period.
Alfuzosin Hydrochloride Extended-Release Tablets are finished prescription oral solid-dose products containing alfuzosin hydrochloride as the sole active ingredient and using a documented sustained, extended, prolonged or modified-release mechanism. The market includes nationally approved 5 mg, 10 mg and other sustained-release strengths; originator brands, branded generics and unbranded generics; multilayer, hydrophilic-matrix, hydrophobic-matrix and mixed-matrix tablets; and blister, bottle and institutional packs sold through retail pharmacies, hospital pharmacies, mail-order pharmacies and public-procurement channels. Immediate-release alfuzosin tablets, active pharmaceutical ingredient, fixed-dose combinations, other alpha blockers, pharmacy dispensing margins, diagnostic services, procedures and clinical-trial supply are excluded. In 2025, the product global weighted average selling price of approximately US$0.39 per tablet, global sales volume of approximately 955 million tablets, and an average gross margin of about 52%. Upstream activities mainly include the production of alfuzosin hydrochloride API, sustained-release matrix materials, binders, fillers, lubricants, coating materials, and pharmaceutical packaging materials. Midstream activities include formulation development, granulation, tableting, coating, dissolution testing, stability testing, bioequivalence studies, regulatory filing, packaging, and batch release. Downstream customers mainly include pharmaceutical wholesalers, retail pharmacies, hospital pharmacies, public procurement agencies, hospitals, and clinics.
Demand is supported by population aging, wider diagnosis of lower urinary tract symptoms and continued use of alpha-blocker therapy for benign prostatic hyperplasia. Once-daily extended-release tablets offer a simpler regimen than immediate-release tablets requiring multiple daily doses.
Unit-volume growth is expected to remain faster than revenue growth. Generic approvals, hospital tenders and public-procurement programs increase access but also reduce the weighted manufacturer selling price.
The 10 mg once-daily formulation is the principal commercial form in the United States and many European markets. Some countries retain 5 mg prolonged-release products administered twice daily, creating differences in prescription volume and tablet consumption.
Modified-release manufacturing presents a higher technical barrier than ordinary immediate-release tablets. Release architecture, food effect, dissolution profiles, stability and bioequivalence must remain consistent during commercial scale-up and post-approval changes.
Administration requirements affect adherence. Current labels generally require the tablet to be swallowed whole, and many products are taken with food or after the same meal each day. Crushing or chewing may alter the intended release profile.
Commercial competition comes from tamsulosin, silodosin and other alpha blockers, as well as five-alpha-reductase inhibitors, tadalafil and fixed-dose treatment strategies. These alternatives limit the share that alfuzosin can obtain from growth in the broader benign prostatic hyperplasia population.
Important commercial and regulatory considerations include postural hypotension, syncope, hepatic impairment, interactions with strong metabolic inhibitors, interval-prolongation caution and disclosure before cataract surgery. These factors influence patient selection, formulary decisions and promotional boundaries.
Report Scope
This report is a detailed and comprehensive analysis for global Alfuzosin Hydrochloride Sustained Release Tablets market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Alfuzosin Hydrochloride Sustained Release Tablets market size and forecasts, in consumption value ($ Million), sales quantity (Million tablets), and average selling prices (US$/tablet), 2021-2032
Global Alfuzosin Hydrochloride Sustained Release Tablets market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Million tablets), and average selling prices (US$/tablet), 2021-2032
Global Alfuzosin Hydrochloride Sustained Release Tablets market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Million tablets), and average selling prices (US$/tablet), 2021-2032
Global Alfuzosin Hydrochloride Sustained Release Tablets market shares of main players, shipments in revenue ($ Million), sales quantity (Million tablets), and ASP (US$/tablet), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Alfuzosin Hydrochloride Sustained Release Tablets
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Alfuzosin Hydrochloride Sustained Release Tablets market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, ADVANZ Pharma, Apotex Inc., Cipla Limited, Sun Pharmaceutical Industries Limited, Unichem Laboratories Limited, Aurobindo Pharma Limited, Wockhardt Limited, Rising Pharma Holdings, Inc., Zentiva Group, a.s., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Alfuzosin Hydrochloride Sustained Release Tablets market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market Segmentation
Market segment by Type
2.5mg
5mg
10mg
Market segment by Prescription Duration
Up to 30 Days
31–90 Days
Above 90 Days
Market segment by Brand Positioning
Originator Premium Brand
Regional Branded Generic
Standard Retail Generic
Institutional Tender Generic
Market segment by Application
Hospital
Clinic
Other
Major players covered
Sanofi
ADVANZ Pharma
Apotex Inc.
Cipla Limited
Sun Pharmaceutical Industries Limited
Unichem Laboratories Limited
Aurobindo Pharma Limited
Wockhardt Limited
Rising Pharma Holdings, Inc.
Zentiva Group, a.s.
Taj Pharmaceuticals Limited
Exelan Pharmaceuticals, Inc.
Lunan Better Pharmaceutical Co., Ltd.
Anxo Pharmaceutical Co., Ltd.
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Alfuzosin Hydrochloride Sustained Release Tablets product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Alfuzosin Hydrochloride Sustained Release Tablets, with price, sales quantity, revenue, and global market share of Alfuzosin Hydrochloride Sustained Release Tablets from 2021 to 2026.
Chapter 3, the Alfuzosin Hydrochloride Sustained Release Tablets competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Alfuzosin Hydrochloride Sustained Release Tablets breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Alfuzosin Hydrochloride Sustained Release Tablets market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Alfuzosin Hydrochloride Sustained Release Tablets.
Chapter 14 and 15, to describe Alfuzosin Hydrochloride Sustained Release Tablets sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Alfuzosin Hydrochloride Sustained Release Tablets. Industry analysis & Market Report on Alfuzosin Hydrochloride Sustained Release Tablets is a syndicated market report, published as Global Alfuzosin Hydrochloride Sustained Release Tablets Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Alfuzosin Hydrochloride Sustained Release Tablets market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.